Aurobindo Pharma

Market Cap: Mid Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE406A01037
NSEID: AUROPHARMA
BSEID: 524804

INR

1,217.10

-6.55 (-0.54%)

BSENSE

Dec 05

BSE+NSE Vol: 52.91 k

{
  "main_header": {
    "sid": 164981,
    "name": "Aurobindo Pharma",
    "stock_name": "Aurobindo Pharma",
    "full_name": "Aurobindo Pharma Ltd.",
    "name_url": "stocks-analysis/aurobindo-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,217.10",
    "chg": -6.55,
    "chgp": "-0.54%",
    "dir": -1,
    "prev_price": "1,223.65",
    "mcapval": "70,689.37 Cr",
    "mcap": "Mid Cap",
    "scripcode": 524804,
    "symbol": "AUROPHARMA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE406A01037",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "52.91 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/aurobindo-pharma-164981-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Aurobindo Pharma technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-aurobindo-pharma-technically-bullish-or-bearish-3739973",
        "imagepath": "",
        "date": "2025-12-02 08:22:45",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Overview of Current Technical Trend</strong></p>\n<p>As of 1 December 2025, Aurobindo Pharma’s technical trend has transitioned from bullish to mildly bullish. This subtle change indicates that while the stock retains positive momentum, the intensity of bullishness has softened. Investors should note that this shift often signals a period of consolidation or cautious optimism rather than an outright reversal.</p>\n<p><strong>Key Technical Indicators: Weekly vs Monthly Perspectives</strong></p>\n<p>Examining the Moving Average Convergence Divergence (MACD), a widely respected momentum indicator, reveals a divergence between weekly and monthly signals. The weekly MACD remains bullish, suggesting that in the short term, buying momentum is intact. Conversely, the monthly MACD is mildly bearish, hin..."
      },
      {
        "title": "Aurobindo Pharma Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aurobindo-pharma-downgraded-to-hold-by-marketsmojo-amid-mixed-financial-and-technical-signals-3740561",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AurobindoPharma_mojoScore_3740561.png",
        "date": "2025-12-02 08:19:09",
        "description": "Aurobindo Pharma, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced changes across quality, valuation, financial trends, and technical indicators. This development comes amid a backdrop of flat quarterly financial results and a complex technical outlook, prompting investors to reassess the stock’s positioning relative to peers and broader market benchmarks."
      },
      {
        "title": "Aurobindo Pharma Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aurobindo-pharma-technical-momentum-shifts-amid-mixed-indicator-signals-3739893",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AurobindoPharma_technicaldot_3739893.png",
        "date": "2025-12-02 08:01:42",
        "description": "Aurobindo Pharma's recent market activity reveals a nuanced shift in price momentum, with technical indicators presenting a blend of bullish and bearish signals. The stock's current price movement and evaluation adjustments suggest a cautious outlook amid evolving market dynamics in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "How has been the historical performance of Aurobindo Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-aurobindo-pharma-3739203",
        "imagepath": "",
        "date": "2025-12-01 23:06:10",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profit Growth</strong></p>\n<p>Over the seven-year period ending March 2025, Aurobindo Pharma’s net sales have shown a consistent upward trend, rising from ₹19,563.55 crores in 2019 to ₹31,723.73 crores in 2025. This represents a compound growth trajectory, with notable acceleration in recent years. The total operating income mirrors this growth, reflecting the company’s expanding market presence and operational scale.</p>\n<p>Operating profit before depreciation and interest (PBDIT) excluding other income increased from ₹3,891.66 crores in 2019 to ₹6,582.79 crores in 2025, indicating improved operational efficiency despite rising raw material and employee costs. The operating profit margin has remained relatively stable, hovering around 21% in recent years, underscoring consistent..."
      },
      {
        "title": "Aurobindo Pharma Sees Shift in Market Assessment Amid Technical and Financial Developments",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aurobindo-pharma-upgraded-to-buy-by-marketsmojo-on-technical-and-valuation-strengths-3732540",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AurobindoPharma_mojoScore_3732540.png",
        "date": "2025-11-27 08:06:36",
        "description": "Aurobindo Pharma has experienced a notable revision in its market evaluation, driven by changes across technical indicators, valuation metrics, financial trends, and overall quality parameters. This shift reflects a nuanced view of the company's current position within the Pharmaceuticals & Biotechnology sector, highlighting both strengths and challenges as investors reassess its outlook."
      },
      {
        "title": "Aurobindo Pharma Technical Momentum Shifts Signal New Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aurobindo-pharma-shifts-to-bullish-momentum-amid-technical-upgrades-3732358",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AurobindoPharma_technicaldot_3732358.png",
        "date": "2025-11-27 08:00:53",
        "description": "Aurobindo Pharma has exhibited a notable shift in its technical momentum, transitioning from a sideways trend to a bullish stance. This change is underscored by a combination of technical indicators including MACD, RSI, moving averages, and volume-based metrics, suggesting evolving market sentiment within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Aurobindo Pharma Forms Golden Cross, Signalling Potential Bullish Breakout",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aurobindo-pharma-forms-golden-cross-signalling-potential-bullish-breakout-3731873",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AurobindoPharma_goldencross_3731873.png",
        "date": "2025-11-26 18:00:16",
        "description": "Aurobindo Pharma has recently witnessed a significant technical development as its 50-day moving average crossed above the 200-day moving average, forming a Golden Cross. This event is widely regarded as a bullish signal, indicating a possible shift in long-term momentum and a potential trend reversal for the pharmaceutical and biotechnology company."
      },
      {
        "title": "Aurobindo Pharma Sees Revision in Market Evaluation Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aurobindo-pharma-upgraded-to-hold-by-marketsmojo-on-11-nov-2025-3730897",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AurobindoPharma_mojoScore_3730897.png",
        "date": "2025-11-26 09:46:39",
        "description": "Aurobindo Pharma's market evaluation has undergone a revision reflecting a nuanced shift in its financial and technical outlook. The pharmaceutical company, classified as a midcap within the Pharmaceuticals & Biotechnology sector, has experienced changes in its assessment metrics driven by a combination of steady quality indicators, valuation considerations, and flat financial trends."
      },
      {
        "title": "Aurobindo Pharma Sees Notable Surge in Derivatives Open Interest Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aurobindo-pharma-sees-sharp-open-interest-surge-amid-mixed-market-signals-3725749",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AurobindoPharma_oi_spurts_by_underlying_3725749.png",
        "date": "2025-11-24 15:00:09",
        "description": "Aurobindo Pharma Ltd. has experienced a significant rise in open interest within its derivatives segment, reflecting evolving market positioning and investor sentiment. This surge accompanies a period of subdued price movement and declining investor participation, signalling nuanced directional bets in the pharmaceutical sector."
      }
    ],
    "total": 689,
    "sid": "164981",
    "stock_news_url": "https://www.marketsmojo.com/news/aurobindo-pharma-164981"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "02-Dec-2025",
      "details": "Submission of notice published in newspapers.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "27-Nov-2025",
      "details": "Submission of newspaper publication.",
      "source": "BSE"
    },
    {
      "caption": "Classification Of US FDA Inspection At Unit-I Of Apitoria Pharma Private Limited A Wholly Owned Subsidiary Of The Company As Voluntary Action Indicated (VAI)",
      "datetime": "14-Nov-2025",
      "details": "Intimation of classification of US FDA inspection at Unit-1 of Apitoria Pharma Private Limited.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Aurobindo Pharma Ltd. has declared <strong>400%</strong> dividend, ex-date: 08 Aug 25",
          "dt": "2025-08-08",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Aurobindo Pharma Ltd. has announced <strong>1:5</strong> stock split, ex-date: 10 Feb 11",
          "dt": "2011-02-10",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Aurobindo Pharma Ltd. has announced <strong>1:1</strong> bonus issue, ex-date: 20 Jul 15",
          "dt": "2015-07-20",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Aurobindo Pharma technically bullish or bearish?

2025-12-02 08:22:45

Overview of Current Technical Trend

As of 1 December 2025, Aurobindo Pharma’s technical trend has transitioned from bullish to mildly bullish. This subtle change indicates that while the stock retains positive momentum, the intensity of bullishness has softened. Investors should note that this shift often signals a period of consolidation or cautious optimism rather than an outright reversal.

Key Technical Indicators: Weekly vs Monthly Perspectives

Examining the Moving Average Convergence Divergence (MACD), a widely respected momentum indicator, reveals a divergence between weekly and monthly signals. The weekly MACD remains bullish, suggesting that in the short term, buying momentum is intact. Conversely, the monthly MACD is mildly bearish, hin...

Aurobindo Pharma Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals

2025-12-02 08:19:09

Aurobindo Pharma, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced changes across quality, valuation, financial trends, and technical indicators. This development comes amid a backdrop of flat quarterly financial results and a complex technical outlook, prompting investors to reassess the stock’s positioning relative to peers and broader market benchmarks.

Aurobindo Pharma Technical Momentum Shifts Amid Mixed Indicator Signals

2025-12-02 08:01:42

Aurobindo Pharma's recent market activity reveals a nuanced shift in price momentum, with technical indicators presenting a blend of bullish and bearish signals. The stock's current price movement and evaluation adjustments suggest a cautious outlook amid evolving market dynamics in the Pharmaceuticals & Biotechnology sector.

How has been the historical performance of Aurobindo Pharma?

2025-12-01 23:06:10

Revenue and Profit Growth

Over the seven-year period ending March 2025, Aurobindo Pharma’s net sales have shown a consistent upward trend, rising from ₹19,563.55 crores in 2019 to ₹31,723.73 crores in 2025. This represents a compound growth trajectory, with notable acceleration in recent years. The total operating income mirrors this growth, reflecting the company’s expanding market presence and operational scale.

Operating profit before depreciation and interest (PBDIT) excluding other income increased from ₹3,891.66 crores in 2019 to ₹6,582.79 crores in 2025, indicating improved operational efficiency despite rising raw material and employee costs. The operating profit margin has remained relatively stable, hovering around 21% in recent years, underscoring consistent...

Aurobindo Pharma Sees Shift in Market Assessment Amid Technical and Financial Developments

2025-11-27 08:06:36

Aurobindo Pharma has experienced a notable revision in its market evaluation, driven by changes across technical indicators, valuation metrics, financial trends, and overall quality parameters. This shift reflects a nuanced view of the company's current position within the Pharmaceuticals & Biotechnology sector, highlighting both strengths and challenges as investors reassess its outlook.

Aurobindo Pharma Technical Momentum Shifts Signal New Market Dynamics

2025-11-27 08:00:53

Aurobindo Pharma has exhibited a notable shift in its technical momentum, transitioning from a sideways trend to a bullish stance. This change is underscored by a combination of technical indicators including MACD, RSI, moving averages, and volume-based metrics, suggesting evolving market sentiment within the Pharmaceuticals & Biotechnology sector.

Aurobindo Pharma Forms Golden Cross, Signalling Potential Bullish Breakout

2025-11-26 18:00:16

Aurobindo Pharma has recently witnessed a significant technical development as its 50-day moving average crossed above the 200-day moving average, forming a Golden Cross. This event is widely regarded as a bullish signal, indicating a possible shift in long-term momentum and a potential trend reversal for the pharmaceutical and biotechnology company.

Aurobindo Pharma Sees Revision in Market Evaluation Amid Mixed Financial Signals

2025-11-26 09:46:39

Aurobindo Pharma's market evaluation has undergone a revision reflecting a nuanced shift in its financial and technical outlook. The pharmaceutical company, classified as a midcap within the Pharmaceuticals & Biotechnology sector, has experienced changes in its assessment metrics driven by a combination of steady quality indicators, valuation considerations, and flat financial trends.

Aurobindo Pharma Sees Notable Surge in Derivatives Open Interest Amid Market Volatility

2025-11-24 15:00:09

Aurobindo Pharma Ltd. has experienced a significant rise in open interest within its derivatives segment, reflecting evolving market positioning and investor sentiment. This surge accompanies a period of subdued price movement and declining investor participation, signalling nuanced directional bets in the pharmaceutical sector.